2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6ca,Plasma cell leukemia (PCL) represents an exceptionally aggressive plasma cell malignancy defined by ≥5% circulating plasma cells in peripheral blood of patients otherwise meeting diagnostic criteria for multiple myeloma (MM), per International Myeloma Working Group consensus. This ultra-high-risk disease exhibits distinctive clinical features including frequent extramedullary involvement, severe cytopenias, hypercalcemia, renal insufficiency, and/or significantly elevated β2-microglobulin and lactate dehydrogenase levels. The molecular landscape includes high-risk cytogenetic abnormalities and mutations that promote accelerated proliferation, apoptotic resistance, immune evasion, and bone marrow microenvironmental independence through dysregulated adhesion molecule and chemokine receptor expression. While autologous stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies improved historical outcomes, the therapeutic paradigm continues to evolve. Novel therapeutic approaches including B-cell maturation antigen (BCMA)-directed therapies (bispecific antibodies and chimeric antigen receptor T-cell therapy), GPRC5D-targeted therapy, and BCL-2 inhibition demonstrate promise in treating both primary and secondary PCL. Despite these advances, PCL remains inadequately studied, with treatment approaches predominantly extrapolated from MM trials where PCL patients have largely been excluded. This review synthesizes current evidence and presents illustrative clinical cases demonstrating practical treatment approaches, while highlighting critical knowledge gaps requiring dedicated prospective clinical trials to meaningfully improve outcomes in this challenging disease entity.31:T6db,Plasma cell leukemia (PCL) represents an exceptionally aggressive plasma cell malignancy defined by ≥5% circulating plasma cells in peripheral blood of patients otherwise meeting diagnostic criteria for multiple myeloma (MM), per International Myeloma Working Group consensus. This ultra-high-risk disease exhibits distinctive clinical features including frequent extramedullary involvement, severe cytopenias, hypercalcemia, renal insufficiency, and/or significantly elevated β2-microglobulin and lactate dehydrogenase levels. The molecular landscape includes high-risk cytogenetic abnormalities and mutations that promote accelerated proliferation, apoptotic resistance, immune evasion, and bone marrow microenvironmental independence through dysregulated adhesion molecule and chemokine receptor expression. While autologous stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies improved historical outcomes, the therapeutic paradigm continues to evolve. Novel therapeutic approaches including B-cell maturation antigen (BCMA)-directed therapies (bispecific antibodies and chimeric antigen receptor T-cell therapy), GPRC5D-targeted therapy, and BCL-2 inhibition demonstrate promise in treating both primary and secondary PCL. Despite these advances, PCL remains inadequately studied, with treatment approaches predominantly extrapolated from MM trials where PCL patients have largely been excluded. This review synthesizes current evidence and presents illustrative clinical cases demonstrating practical treatment approaches, while highlighting critical knowledge gaps requiring dedicated prospective clinical trials to meaningfully improve outcomes in this challenging disease entity.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"BCL-2 Inhibitor: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on BCL-2 Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/BCL-2%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"BCL-2 Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/BCL-2%20Inhibitor\"}]}}"}}]],["$","$L2f",null,{"title":"BCL-2 Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: BCL-2 Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.1016/j.jinf.2026.106840","pmid":"42700823","title":"Risk Stratification for Tuberculosis Reactivation in Patients Receiving Biological and Non-biological Immunomodulators: A Review of Current Literature","journal_title":"Journal of Infection","journal_issn":"0163-4453","published_at":"2026-09-06T00:00:00.000Z","url":"https://doi.org/10.1016/j.jinf.2026.106840","source_score":40,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-09T06:21:07.655Z","updated_at":"2026-09-09T06:21:07.655Z","tags":[{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"condition","value":"Latent Tuberculosis Infection","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"condition","value":"Tuberculosis","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Biologic Immunomodulator","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Glucocorticoid","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Integrin Antagonist","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Interleukin Antagonist","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"modality","value":"Proteasome Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jinf.2026.106840","tag_type":"warning","value":"No sample size is applicable — this is a review article with no primary patient cohort. Impact flag 'practice_changing' applied because the review consolidates FDA/EMA regulatory guidance across nine drug classes into a single actionable framework, which is clinically significant; however, it is based on synthesized rather than new trial evidence. Sex of study population is not reported, as expected for a literature review.","value_numeric":null}],"summaries":{"what_studied":"This narrative review synthesizes current evidence on latent tuberculosis infection (LTBI) reactivation mechanisms and risk levels associated with nine major classes of immunosuppressive agents (biological and non-biological), and collates FDA and EMA prescribing guidance on TB screening across these drug classes.","key_result":"Multiple immunosuppressant classes — including B- and T-cell depleting agents, interleukin antagonists, cytokine antagonists, integrin antagonists, immune checkpoint inhibitors, kinase inhibitors, proteasome inhibitors, calcineurin inhibitors, glucocorticoids, and BCL-2 inhibitors — carry meaningful risk of LTBI reactivation, underscoring the need for systematic TB screening and preventive therapy before initiation.","limitations":"As a narrative review, it does not perform a meta-analysis or quantify comparative reactivation rates across drug classes; risk estimates depend on the quality and heterogeneity of the underlying primary literature. No original patient-level data are presented.","practice_takeaway":"Before starting any major immunosuppressive agent, screen patients for LTBI using both tuberculin skin test and IGRA, and initiate preventive treatment per FDA/EMA guidance — especially for TNF antagonists, JAK inhibitors, and T/B-cell depleting therapies, which carry the highest reactivation concern. Maintain vigilance for TB reactivation throughout the treatment course, even in patients who screened negative at baseline."}},{"doi":"10.1056/nejmoa2602804","pmid":"42685316","title":"Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia","journal_title":"New England Journal of Medicine","journal_issn":"0028-4793","published_at":"2026-09-02T00:00:00.000Z","url":"https://doi.org/10.1056/nejmoa2602804","source_score":210,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-08T06:32:05.061Z","updated_at":"2026-09-08T06:32:05.061Z","tags":[{"paper_doi":"10.1056/nejmoa2602804","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"modality","value":"Induction Chemotherapy","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"sample_size","value":"n=172","value_numeric":172},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"warning","value":"Funding by AbbVie (venetoclax manufacturer) is a potential source of industry bias.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"warning","value":"Impact flag 'practice_changing' applied cautiously — this is a phase 2 trial; phase 3 confirmation is needed before routine adoption. The authors themselves note this limitation.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"warning","value":"Overall survival data were not reported as mature, so long-term benefit remains uncertain.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2602804","tag_type":"warning","value":"The trial excluded key AML subgroups (FLT3-mutated, CBF fusion, NPM1-mutated patients <60 years), so findings should not be extrapolated to those populations.","value_numeric":null}],"summaries":{"what_studied":"This multicenter phase 2 RCT (PARADIGM, NCT04801797) compared azacitidine–venetoclax vs. induction chemotherapy in 172 previously untreated, induction-eligible adults with AML (excluding CBF fusions, FLT3 mutations, and NPM1 mutations in patients <60 years), with event-free survival as the primary endpoint over a median follow-up of 21.9 months.","key_result":"Azacitidine–venetoclax significantly improved median event-free survival vs. induction chemotherapy (14.5 months vs. 6.2 months; HR 0.57, 95% CI 0.39–0.84; P=0.002), with lower rates of grade ≥3 infection (28% vs. 41%) and grade ≥3 hemorrhage (2% vs. 12%).","limitations":"Phase 2 trial only — not powered or designed as a definitive phase 3 study, limiting practice-changing conclusions. Key molecular subgroups (FLT3, NPM1 <60 years, CBF) were excluded, restricting generalizability. Overall survival data are not yet mature at median follow-up of 21.9 months.","practice_takeaway":"For fit AML patients without FLT3/NPM1/CBF alterations — especially older adults with adverse-risk disease — azacitidine–venetoclax may offer a less toxic and more effective alternative to induction chemotherapy. Clinicians should await phase 3 confirmation before broadly replacing standard induction."}},{"doi":"10.1038/s41375-026-03119-6","pmid":"42675141","title":"Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study","journal_title":"Leukemia","journal_issn":"0887-6924","published_at":"2026-08-31T00:00:00.000Z","url":"https://doi.org/10.1182/blood-2025-874","source_score":9,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-08T06:32:01.399Z","updated_at":"2026-09-08T06:32:01.399Z","tags":[{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"condition","value":"TP53-Mutant Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"generic","value":"decitabine","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"sample_size","value":"n=321","value_numeric":321},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"warning","value":"Retrospective registry data may underrepresent important treatment details such as transplant consolidation rates, which could confound survival comparisons.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"warning","value":"The DOI and URL in the source appear to reference different identifiers (Leukemia journal DOI vs. Blood abstract URL); the primary publication venue should be confirmed.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03119-6","tag_type":"warning","value":"The sample size of 321 HMA-treated patients is drawn from a larger registry of 652 TP53-MT AML patients; the analysis population for direct comparisons is the propensity-matched subset, which may be smaller—exact matched-cohort N is not specified in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This multicenter retrospective study compared outcomes of decitabine (DEC)- vs. azacitidine (AZA)-based induction—including combinations with venetoclax (VEN)—in 321 newly diagnosed TP53-mutant AML patients from the COMMAND registry (652 total TP53-MT AML patients identified).","key_result":"In the propensity score-matched cohort, DEC and AZA showed no significant difference in EFS (P=0.920) or OS (P=0.927). Median OS was 5.7, 7.1, 9.2, and 7.1 months for DEC+VEN, AZA+VEN, DEC, and AZA, respectively; 12-month OS rates were 31%, 23%, 29%, and 32%. Multi-hit TP53 status—not mutation subtype—was independently associated with worse EFS and OS.","limitations":"Retrospective design with inherent selection bias; propensity score matching cannot fully adjust for unmeasured confounders; no data on post-induction therapies (e.g., transplant rates) stratified by regimen.","practice_takeaway":"Choice between AZA- and DEC-based regimens (with or without venetoclax) does not appear to meaningfully change survival in newly diagnosed TP53-mutant AML. Clinicians should factor in multi-hit TP53 status as a key prognostic marker when counseling patients."}},{"doi":"10.1080/17474086.2026.2720126","pmid":"42613865","title":"Treatment of older adults with newly diagnosed\n FLT3\n -mutated AML: focus on lower-intensity triplet regimens","journal_title":"Expert Review of Hematology","journal_issn":"1747-4086","published_at":"2026-08-19T00:00:00.000Z","url":"https://doi.org/10.1080/17474086.2026.2720126","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-23T07:33:10.677Z","updated_at":"2026-08-23T07:33:10.677Z","tags":[{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"condition","value":"FLT3-Mutated AML","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"modality","value":"FLT3 Inhibitor","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"warning","value":"No sample size is reported; this is a narrative review synthesizing existing literature, not a primary study.","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"warning","value":"Study design is described as a narrative review; it is not a systematic review or meta-analysis, so selection bias in literature inclusion cannot be excluded.","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the authors' positioning of triplet regimens as a 'potential new standard-of-care,' but RCT confirmation is explicitly still pending — clinicians should weigh this accordingly.","value_numeric":null},{"paper_doi":"10.1080/17474086.2026.2720126","tag_type":"warning","value":"The specific FLT3 inhibitors evaluated (e.g., gilteritinib, quizartinib, midostaurin) are not named in the abstract; tag details for individual agents could not be extracted.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates frontline treatment options for older adults with newly diagnosed FLT3-mutated AML who are unfit for intensive chemotherapy, focusing on triplet regimens combining a hypomethylating agent (HMA) + venetoclax + FLT3 inhibitor, based on a PubMed/MEDLINE literature search through June 2026.","key_result":"HMA + venetoclax + FLT3 inhibitor triplet regimens demonstrated very high response rates and improved long-term survival in older adults with FLT3-mutated AML when administered with dose optimization and supportive care; however, no randomized controlled trial data are yet available to confirm superiority over the current standard doublet (HMA + venetoclax).","limitations":"- No RCT data exist yet comparing triplet vs. doublet regimens; evidence is from non-randomized, likely single-arm or retrospective studies.\n- Safe delivery requires close monitoring and expertise most available at specialized academic centers, limiting generalizability.\n- Review scope is limited to publications through June 2026, and the field is rapidly evolving.","practice_takeaway":"Consider HMA + venetoclax + FLT3 inhibitor triplet regimens—with careful dose optimization and robust supportive care—for older, unfit patients with FLT3-mutated AML, particularly FLT3-ITD, where doublet therapy outcomes remain poor. Referral to or consultation with specialized academic centers is advisable given the complexity of managing triplet regimen toxicity."}},{"doi":"10.1182/blood.2026034611","pmid":"42520193","title":"OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2026034611","source_score":6,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:14.679Z","updated_at":"2026-07-31T13:37:14.679Z","tags":[{"paper_doi":"10.1182/blood.2026034611","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"sample_size","value":"n=169","value_numeric":169},{"paper_doi":"10.1182/blood.2026034611","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"warning","value":"Non-inferiority was not demonstrated, but the confidence interval crossed zero — the trial was not powered to definitively establish inferiority of AV14 either; interpret with caution.","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"warning","value":"Overall survival and longer-term outcomes were not reported; conclusions are limited to CR rates after 2 cycles.","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"warning","value":"Phase 2 design limits generalizability; authors note findings require validation especially as triplet regimens emerge.","value_numeric":null},{"paper_doi":"10.1182/blood.2026034611","tag_type":"warning","value":"Subgroup findings (NPM1/IDH2 benefit with 28-day venetoclax) are hypothesis-generating only and not confirmed in a powered analysis.","value_numeric":null}],"summaries":{"what_studied":"OPTI-AML was a prospective randomized phase 2 trial comparing 28-day (AV28) vs. 14-day (AV14) venetoclax with azacitidine (75 mg/m² × 7 days) for cycles 1–2 in genomically unselected newly diagnosed AML patients ≥60 years (n=169, enrolled 2023–2025).","key_result":"CR rate was 49.4% (AV28, n=83) vs. 43% (AV14, n=86); difference of 6.4% [90% CI: −6.1% to 19.0%], **not meeting non-inferiority criteria**. Composite CR was 80.7% vs. 68.6%; MRD negativity was similar (77.6% vs. 76.5%). NPM1/IDH2-mutated patients had notably higher CR with AV28 (60.9% vs. 33.3%), while other subgroups had equivalent CR (~45%). Grade ≥3 adverse events and early mortality were similar between arms.","limitations":"- Phase 2 trial; underpowered to confirm subgroup findings (e.g., NPM1/IDH2 benefit with AV28).\n- Non-inferiority not demonstrated, but the CI crossed zero — true inferiority of AV14 also unproven.\n- Only cycles 1–2 evaluated; longer-term outcomes and OS data not reported.","practice_takeaway":"Do not routinely substitute 14-day for 28-day venetoclax in unselected older AML patients — non-inferiority was not established, and NPM1/IDH2-mutated patients appeared to benefit from the full 28-day schedule. Abbreviated dosing may still be appropriate in select patients with prolonged cytopenias, but prospective validation in larger studies is needed."}},{"doi":"10.1158/2159-8290.cd-26-0251","pmid":"42484277","title":"Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors","journal_title":"Cancer Discovery","journal_issn":"2159-8274","published_at":"2026-07-22T00:00:00.000Z","url":"https://doi.org/10.1158/2159-8290.cd-26-0251","source_score":69,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-28T14:02:34.245Z","updated_at":"2026-07-28T14:02:34.245Z","tags":[{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"condition","value":"Chronic Lymphocytic Leukemia","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"generic","value":"bexobrutideg","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"generic","value":"zelebrudomide","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"modality","value":"BTK Degrader","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"modality","value":"BTK Inhibitor","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"study_design","value":"Translational/Correlative Study (Phase I Trial Biomarker Analysis)","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"warning","value":"Sample size not explicitly reported in the abstract; 'small patient numbers' is inferred from the phase I context — exact N is unavailable.","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"warning","value":"Study design label reflects a biomarker/correlative analysis embedded within phase I trials rather than a standalone trial design.","value_numeric":null},{"paper_doi":"10.1158/2159-8290.cd-26-0251","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied because the study identifies a novel pan-resistance mechanism and a potential mitigation strategy, but the combination data are preclinical/early-phase and not yet validated in a larger trial.","value_numeric":null}],"summaries":{"what_studied":"Serial CLL samples from patients in phase I trials of BTK degraders (zelebrudomide and bexobrutideg) were sequenced to identify mechanisms of clinical resistance in BTK inhibitor-resistant CLL.","key_result":"A recurrent BTK A428D mutation was found to expand at relapse and confer pan-resistance to both BTK inhibitors and degraders; crystal structure showed the mutant aspartate sterically clashes with the adenine ring of ATP and the adenine-mimetic moiety shared by BTK inhibitors and degraders. Combining a BTK degrader with venetoclax mitigated expansion of BTK A428D clones.","limitations":"Phase I trial samples only; small patient numbers typical of early-phase studies; findings are primarily molecular/structural with limited clinical outcomes data on the venetoclax combination strategy.","practice_takeaway":"BTK A428D is a pan-resistance mutation to watch for in CLL patients progressing on BTK degraders — it pre-exists before therapy and expands under selective pressure. Combining BTK degraders with venetoclax may help suppress this resistance mechanism and warrants prospective evaluation."}},{"doi":"10.1158/1078-0432.ccr-25-4843","pmid":"42439804","title":"The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML.","journal_title":"Clinical Cancer Research","journal_issn":"1078-0432","published_at":"2026-07-13T00:00:00.000Z","url":"https://doi.org/10.1158/1078-0432.ccr-25-4843","source_score":40,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-16T13:37:18.213Z","updated_at":"2026-07-16T13:37:18.213Z","tags":[{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"condition","value":"TP53-Mutant AML","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"condition","value":"Venetoclax-Resistant AML","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"generic","value":"NTX-301","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"study_design","value":"Pre-clinical Study","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"warning","value":"Age group tagged as 'mixed' because PDX models may originate from patients of varying ages; no specific patient population was enrolled.","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"warning","value":"NTX-301 is investigational with no published clinical trial data; all efficacy and mechanistic findings are pre-clinical only.","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"warning","value":"Sample size (number of cell lines, PDX models) is not specified in the abstract, limiting assessment of pre-clinical breadth.","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-4843","tag_type":"warning","value":"The paper was published July 13, 2026 — very recent; no peer commentary or replication studies are available yet.","value_numeric":null}],"summaries":{"what_studied":"Pre-clinical evaluation of NTX-301, a next-generation hypomethylating agent (HMA), versus 5-azacytidine (5-AZA) in venetoclax (VEN)-resistant and TP53-mutant AML models, including xenograft and patient-derived xenograft (PDX) systems, using cell viability assays, RNA-seq, methylation profiling, and CyTOF mass cytometry.","key_result":"NTX-301 showed superior efficacy over 5-AZA in 5-AZA- or VEN-resistant AML, synergized with VEN in VEN/HMA-resistant and TP53-mutant AML (combination index <1), extended survival by ≥45% in xenograft and PDX models, and activated Hippo signaling (via LATS1/2 demethylation) and p53 pathway more potently than 5-AZA.","limitations":"Entirely pre-clinical (cell line and mouse models); no clinical data in humans yet. The study does not address pharmacokinetics, tolerability, or dosing in patients. Resistance mechanisms were modeled in vitro and may not fully recapitulate clinical resistance.","practice_takeaway":"NTX-301 is not yet clinically available, but these findings support its investigation in patients with VEN-resistant or TP53-mutant AML—populations with very poor outcomes on current HMA/VEN regimens. Clinicians should watch for early-phase trials of NTX-301 in these high-risk AML subgroups."}},{"doi":"10.1111/bjh.70620","pmid":"42438219","title":"Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3\n SYMPATICO\n study","journal_title":"British Journal of Haematology","journal_issn":"0007-1048","published_at":"2026-07-12T00:00:00.000Z","url":"https://doi.org/10.1111/bjh.70620","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-20T13:36:02.108Z","updated_at":"2026-07-20T13:36:02.108Z","tags":[{"paper_doi":"10.1111/bjh.70620","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"brand","value":"Imbruvica","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"condition","value":"Mantle Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"generic","value":"ibrutinib","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"modality","value":"BTK Inhibitor","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"warning","value":"Sample size tag was omitted as the total N was not available in the provided source text.","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously based on phase 3 final analysis designation; full data review is recommended before changing clinical practice.","value_numeric":null},{"paper_doi":"10.1111/bjh.70620","tag_type":"warning","value":"The source provided contains only the paper title, DOI, journal, and publication date — no abstract or full text was included. Summary content is inferred from the study title and known trial design (SYMPATICO phase 3); specific numerical outcomes (e.g., median PFS, OS, response rates, sample size) could not be extracted and should be verified against the full publication.","value_numeric":null}],"summaries":{"what_studied":"The SYMPATICO phase 3 trial evaluated ibrutinib plus venetoclax versus ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL), reporting final analysis outcomes.","key_result":"The combination of ibrutinib plus venetoclax demonstrated improved progression-free survival and other efficacy endpoints over ibrutinib plus placebo in R/R MCL patients, consistent with earlier interim results; specific final numerical data (e.g., median PFS, OS rates) were not extractable from the provided source text.","limitations":"Full numerical results and patient-level details are not available from the provided abstract/metadata alone, limiting precise quantification of effect sizes and safety data.","practice_takeaway":"For patients with R/R MCL, the SYMPATICO final analysis supports ibrutinib plus venetoclax as a combination regimen with superior efficacy over ibrutinib monotherapy. Clinicians should consider this doublet in eligible R/R MCL patients, weighing additive toxicity profiles."}},{"doi":"10.1038/s41375-026-03029-7","pmid":"42380663","title":"Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms","journal_title":"Leukemia","journal_issn":"0887-6924","published_at":"2026-06-30T00:00:00.000Z","url":"https://doi.org/10.1038/s41375-026-03029-7","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-09T13:35:58.474Z","updated_at":"2026-07-09T13:35:58.474Z","tags":[{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"condition","value":"Clonal Cytopenia of Undetermined Significance","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"condition","value":"Myelodysplastic Neoplasms","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"generic","value":"decitabine","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"modality","value":"Multiplex Immunofluorescence Imaging","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"sample_size","value":"n=99","value_numeric":99},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"study_design","value":"Longitudinal Cohort Study with Cross-Sectional Diagnostic Component","value_numeric":null},{"paper_doi":"10.1038/s41375-026-03029-7","tag_type":"warning","value":"The study design combines cross-sectional diagnostic and longitudinal samples; the level of evidence reflects the best applicable single-institution observational design without external validation. The 'practice_changing' impact flag is applied cautiously—MDS-MAPS is a research tool not yet validated for routine clinical use. Sample sizes for key subanalyses (e.g., blast progression modeling, n=16) are small, limiting generalizability. The total sample size tag reflects biopsy samples; unique patient count is lower (n=49 MDS/CCUS + 21 controls).","value_numeric":null}],"summaries":{"what_studied":"Whole-slide multiplex immunofluorescence (MxIF) imaging with single-cell spatial phenotyping was applied to bone marrow trephines from MDS patients (n=36 diagnostic, n=29 longitudinal), CCUS precursors (n=13), and normal controls (n=21), totaling >5 million spatially resolved cells, to map microarchitectural remodeling and derive a composite Microarchitectural Perturbation Score (MDS-MAPS) from 82 cellular and spatial features.","key_result":"In leave-one-patient-out cross-validation, MDS-MAPS distinguished remission from active disease with AUC 0.883 vs. AUC 0.660 for blast percentage alone, and separated low-blast MDS from CCUS with AUC 0.815 vs. AUC 0.706–0.706 for VAF-based mutation burden; mixed-effects modeling confirmed MAPS decreased in remission independent of blast burden, with architectural normalization during remission and re-emergence at relapse.","limitations":"- Small longitudinal cohort (14 MDS patients, 29 serial biopsies; blast progression modeling limited to n=16).\n- MDS-MAPS weights were expert-curated, introducing potential subjectivity, and random slopes were not modeled due to limited serial samples per patient.\n- Whole-slide images require institutional data use agreements; external validation in independent cohorts was not performed.","practice_takeaway":"Quantitative bone marrow microarchitecture scoring (MDS-MAPS) outperforms blast counting for detecting remission and distinguishing CCUS from low-blast MDS—consider spatial imaging biomarkers as a complement to standard blast enumeration and molecular testing in MDS assessment. Architectural normalization may serve as an early signal of treatment response even when blast counts remain low."}},{"doi":"10.1038/s41375-026-02996-1","pmid":"42297916","title":"Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia","journal_title":"Leukemia","journal_issn":"0887-6924","published_at":"2026-06-15T00:00:00.000Z","url":"https://doi.org/10.1038/s41375-026-02996-1","source_score":14,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-18T13:24:19.133Z","updated_at":"2026-06-18T13:24:19.133Z","tags":[{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"condition","value":"Myelodysplasia-Related AML","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"modality","value":"BRAF Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"sample_size","value":"n=5779","value_numeric":5779},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"warning","value":"Impact flag 'practice_changing' is tentative; the drug sensitivity findings are exploratory and not from a prospective trial.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"warning","value":"The full text content retrieved is almost entirely PDF metadata and a supplemental figure label — the abstract was the primary source for all summary content. Clinical details, survival curves, and drug sensitivity data could not be independently verified from the full text.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02996-1","tag_type":"warning","value":"The study includes relapsed/refractory and secondary AML cases mixed with newly diagnosed — survival analyses may reflect a heterogeneous population.","value_numeric":null}],"summaries":{"what_studied":"This study analyzed BRAF mutations in 5,779 consecutive AML patients treated at two major U.S. cancer centers, characterizing clinical/molecular features and outcomes. A subset underwent single-cell multiomic profiling to assess co-mutation patterns, clonality, and immunophenotypes.","key_result":"BRAF mutations occurred in ~1% of patients (50/5,779), with 21 newly diagnosed AML, 9 relapsed/refractory, and 20 newly diagnosed secondary AML cases. Mutations were enriched in myelodysplasia-related AML (AML-MR) and mostly non-V600 hotspot. BRAF mutations co-occurred with other signaling mutations **within the same cell** — diverging from RAS-mutant AML behavior. Overall survival was poor with current treatments, including venetoclax-based regimens.","limitations":"- Retrospective cohort from only two U.S. centers, limiting generalizability.\n- Small absolute number of BRAF-mutant cases (n=50) constrains statistical power for subgroup analyses.\n- Drug sensitivity data are exploratory and not validated in prospective clinical trials.","practice_takeaway":"BRAF-mutant AML (~1% of cases) carries poor prognosis with standard and venetoclax-based therapy — clinicians should consider molecular testing and explore targeted BRAF/MEK inhibitor strategies in this subset. Single-cell data suggest intra-clonal signaling co-mutations, which may inform resistance mechanisms and combination treatment design."}},{"doi":"10.1002/hem3.70403","pmid":null,"title":"EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation","journal_title":"HemaSphere","journal_issn":"2572-9241","published_at":"2026-06-10T00:00:00.000Z","url":"https://doi.org/10.1002/hem3.70403","source_score":29,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-06-15T13:21:47.059Z","updated_at":"2026-06-15T13:21:47.059Z","tags":[{"paper_doi":"10.1002/hem3.70403","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"brand","value":"Calquence","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"brand","value":"Gazyva","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"brand","value":"Jaypirca","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"condition","value":"Chronic Lymphocytic Leukemia","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"condition","value":"Richter Transformation","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"generic","value":"acalabrutinib","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"generic","value":"obinutuzumab","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"generic","value":"pirtobrutinib","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"modality","value":"Anti-CD20 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"modality","value":"BTK Inhibitor","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"warning","value":"Level of evidence set to '1' reflecting a formal expert consensus/professional society guideline; individual recommendation grades within the full document may vary and are not detailed in the abstract.","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"warning","value":"Pirtobrutinib is described as approved for covalent BTK inhibitor-exposed relapsed/refractory CLL, but the specific EMA approval status for pirtobrutinib is not explicitly confirmed in the abstract text.","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"warning","value":"Sample size tag omitted — this is a guideline document, not a primary study with an enrolled patient cohort.","value_numeric":null},{"paper_doi":"10.1002/hem3.70403","tag_type":"warning","value":"Sex and age_group tags are inferred as 'adult' based on CLL epidemiology context; the abstract does not explicitly specify population demographics.","value_numeric":null}],"summaries":{"what_studied":"EHA 2026 consensus guidelines covering the full management spectrum of chronic lymphocytic leukemia (CLL) and Richter transformation — from initial diagnosis and active surveillance through first-line and relapsed/refractory treatment decision-making, incorporating patient advocacy input for the first time.","key_result":"Key updates include EMA-approved time-limited acalabrutinib + venetoclax ± obinutuzumab as a first-line option, and continuous pirtobrutinib for patients previously exposed to covalent BTK inhibitors in the relapsed/refractory setting; Richter transformation is now explicitly addressed within the guideline scope.","limitations":"Consensus-based guideline rather than a primary study; evidence grading specifics and individual recommendation strengths are not detailed in the abstract.","practice_takeaway":"Clinicians can now offer a time-limited, chemo-free doublet/triplet (acalabrutinib + venetoclax ± obinutuzumab) up front for CLL, and should consider pirtobrutinib for patients who progress on or are intolerant of covalent BTK inhibitors. Treatment decisions should integrate both disease-specific and patient-specific factors, including surveillance for Richter transformation."}},{"doi":"10.1038/s41375-026-02998-z","pmid":"42260111","title":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia","journal_title":"Leukemia","journal_issn":"0887-6924","published_at":"2026-06-08T00:00:00.000Z","url":"https://doi.org/10.1038/s41375-026-02998-z","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-18T13:24:19.515Z","updated_at":"2026-06-18T13:24:19.515Z","tags":[{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"condition","value":"T-Cell Acute Lymphoblastic Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"generic","value":"dexamethasone","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"generic","value":"navitoclax","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"generic","value":"vincristine","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"modality","value":"BCL-XL Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"sample_size","value":"n=20","value_numeric":20},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"study_design","value":"Pre-clinical In Vivo Study","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"warning","value":"Sample size tag reflects the 20 T-ALL cell lines screened; PDX experiments used small groups (n=3–6 mice per arm), limiting statistical power.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"warning","value":"Significant conflict of interest: the study was funded by Servier Laboratories and the majority of co-authors are Servier employees.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the potential translational significance highlighted by the authors, not established clinical evidence.","value_numeric":null},{"paper_doi":"10.1038/s41375-026-02998-z","tag_type":"warning","value":"This is entirely pre-clinical research (cell lines and NSG mouse PDX models); no human pharmacokinetic, efficacy, or safety data are available.","value_numeric":null}],"summaries":{"what_studied":"Pre-clinical evaluation of ADC-CD7-BCL-XLi — a novel anti-CD7 antibody-drug conjugate carrying a BCL-XL-selective inhibitor payload — in T-ALL cell lines and patient-derived xenograft (PDX) mouse models, including as monotherapy and in combination with venetoclax ± vincristine/dexamethasone chemotherapy.","key_result":"ADC-CD7-BCL-XLi killed 15/20 T-ALL cell lines (IC50 10 pM–4 nM) and reduced leukemia burden in 5/6 T-ALL PDXs without causing thrombocytopenia (vs. dose-limiting platelet drops with navitoclax/A-1331852). Combined ADC-CD7-BCL-XLi + venetoclax extended survival to ~140 days vs. ~83–102 days with ADC alone. Adding chemotherapy (vincristine + dexamethasone) led to apparent cure in 3/5 mice (T-ALL #2, disease-free to day 491) and 5/5 mice (T-ALL #3, disease-free to day 300).","limitations":"- Entirely pre-clinical (NSG mouse PDX models); no human clinical data yet.\n- Resistance emerged after 3–4 iterative doses, linked to BCL-2/BCL-XL upregulation, ACK1 activation, and CD7 downmodulation.\n- Significant industry funding (Servier) with many co-authors as Servier employees.","practice_takeaway":"This ADC delivers BCL-XL inhibition directly to CD7+ leukemic cells, bypassing the platelet toxicity that has stalled systemic BCL-XL inhibitors in T-ALL; if clinical trials confirm these findings, it could serve as a bridge to HSCT or be integrated into frontline regimens alongside venetoclax and chemotherapy."}},{"doi":"10.1182/blood.2026034043","pmid":"42227701","title":"Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-06-02T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2026034043","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:31.816Z","updated_at":"2026-06-10T14:24:31.816Z","tags":[{"paper_doi":"10.1182/blood.2026034043","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"condition","value":"NPM1-Mutated Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"generic","value":"ziftomenib","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"modality","value":"Menin Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"sample_size","value":"n=67","value_numeric":67},{"paper_doi":"10.1182/blood.2026034043","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"study_design","value":"Phase 1 Clinical Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"warning","value":"Brand tag 'Venclexta' added for venetoclax; no proprietary brand name was reported for ziftomenib in the abstract.","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"warning","value":"Median overall survival was not reached, limiting long-term survival interpretation.","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"warning","value":"MRD negativity data were available for only 18 of 48 patients at the 600 mg dose, which may introduce selection bias in MRD reporting.","value_numeric":null},{"paper_doi":"10.1182/blood.2026034043","tag_type":"warning","value":"The 'practice_changing' impact flag reflects FDA-approved monotherapy status of ziftomenib and strong triplet results, but this is a single-arm phase 1 study — randomized confirmation is pending.","value_numeric":null}],"summaries":{"what_studied":"Phase 1 trial (KOMET-007) evaluating ziftomenib (200/400/600 mg once daily, oral menin inhibitor) combined with venetoclax and azacitidine in adults with relapsed/refractory NPM1-mutated AML; 67 patients treated, median age 66 years, 55% with prior venetoclax exposure.","key_result":"At the 600 mg dose (n=48), composite complete remission (CRc) rate was 46% overall; 70% in venetoclax-naïve vs. 24% in venetoclax-exposed patients. MRD negativity (<0.01%) was achieved in 67% (12/18) of evaluable patients. Median duration of response was 8.6 months; median overall survival was not reached.","limitations":"Phase 1 study without a randomized control arm, limiting comparative efficacy conclusions. Small subgroup sizes (especially venetoclax-naïve vs. -exposed) reduce precision of subgroup estimates. MRD negativity data available for only 18 of 48 patients at the 600 mg dose.","practice_takeaway":"For R/R NPM1-mutated AML, ziftomenib 600 mg with venetoclax/azacitidine produced a 70% CRc in venetoclax-naïve patients and was manageable in terms of safety, including low rates of differentiation syndrome (2 patients, grade 3) and QTc prolongation. Clinicians should note substantially lower responses (24% CRc) in venetoclax-pretreated patients, which may inform treatment sequencing decisions."}},{"doi":"10.1182/blood.2025032145","pmid":"42066212","title":"How I Treat Plasma Cell Leukemia","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-05-01T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025032145","source_score":33,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-06","doi":"10.1182/blood.2025032145","days":"14","issn":"0006-4971","rank":"6","field":"Clinical Medicine","score":"33","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/blood.2025032145","title":"How I Treat Plasma Cell Leukemia.","journal":"Blood","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"42066212","conclusions":"","publication_date":"2026-05-01T00:00:00"},"crossref":{"DOI":"10.1182/blood.2025032145","URL":"https://doi.org/10.1182/blood.2025032145","ISSN":["0006-4971","1528-0020"],"link":[{"URL":"https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2025032145/2516783/blood.2025032145.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2025032145/2516783/blood.2025032145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["How I Treat Plasma Cell Leukemia"],"author":[{"given":"Samer","family":"Al Hadidi","sequence":"first","affiliation":[{"name":"UT Southwestern Medical Center, Dallas, Texas, United States"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Pennsylvania, United States"}]},{"given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas, United States"}]}],"issued":{"date-parts":[[2026,5,1]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":null,"created":{"date-time":"2026-05-01T18:41:02Z","timestamp":1777660862000,"date-parts":[[2026,5,1]]},"indexed":{"date-time":"2026-05-04T18:15:19Z","timestamp":1777918519818,"date-parts":[[2026,5,4]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/blood/article/doi/10.1182/blood.2025032145/568165/How-I-Treat-Plasma-Cell-Leukemia"}},"subtitle":[],"deposited":{"date-time":"2026-05-01T18:41:02Z","timestamp":1777660862000,"date-parts":[[2026,5,1]]},"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"published":{"date-parts":[[2026,5,1]]},"publisher":"American Society of Hematology","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1182/blood.2019cm0000","article-number":"blood.2025032145","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood Journal"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,1]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1182/blood.2025032145","is_oa":false,"title":"How I Treat Plasma Cell Leukemia","updated":"2026-05-05T11:59:32+00:00","published_date":"2026-05-01","best_oa_location":null}},"created_at":"2026-05-07T22:51:14.232Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1182/blood.2025032145","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"condition","value":"Plasma Cell Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"Autologous Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"Immunomodulatory Drug","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"modality","value":"Proteasome Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"warning","value":"Level of evidence set to 5 (expert opinion/narrative review); no prospective trial data specific to PCL were reported.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"warning","value":"No sample size tag was applied — this is a narrative review with no single study population; individual cases are illustrative only.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"warning","value":"Publication date is listed as 2026-05-01, which is in the future relative to most available trial data; recency of cited evidence could not be verified from the abstract alone.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032145","tag_type":"warning","value":"Study design labeled 'Narrative Review' rather than 'Systematic Review' as no formal systematic search methodology is described in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This review synthesizes current evidence on the diagnosis and treatment of plasma cell leukemia (PCL), defined as ≥5% circulating plasma cells in peripheral blood in patients meeting MM criteria, covering established and novel therapeutic approaches including BCMA-directed bispecific antibodies, CAR-T cell therapy, GPRC5D-targeted therapy, and BCL-2 inhibition.","key_result":"Novel agents targeting BCMA (bispecific antibodies, CAR-T) and GPRC5D, along with BCL-2 inhibition, show promise in both primary and secondary PCL; however, no robust prospective trial data specific to PCL exist, as these patients have largely been excluded from MM trials.","limitations":"- Treatment evidence is almost entirely extrapolated from MM trials that excluded PCL patients, with no dedicated prospective RCTs in PCL.\n- The rarity of PCL means most guidance comes from case series, retrospective data, and illustrative clinical cases presented in this review.\n- High-risk molecular features and extramedullary disease make outcomes difficult to generalize across patients.","practice_takeaway":"Consider BCMA-directed therapies (bispecific antibodies or CAR-T) and GPRC5D-targeted agents for PCL patients, particularly those with relapsed/refractory disease, while recognizing that evidence is largely extrapolated from MM studies. Enrollment in dedicated prospective PCL trials should be strongly prioritized whenever available."}},{"doi":"10.1002/ajh.70328","pmid":"42035228","title":"Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia","journal_title":"American Journal of Hematology","journal_issn":"0361-8609","published_at":"2026-04-25T00:00:00.000Z","url":"https://doi.org/10.1002/ajh.70328","source_score":17,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-10T13:20:34.192Z","updated_at":"2026-05-10T13:20:34.192Z","tags":[{"paper_doi":"10.1002/ajh.70328","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"generic","value":"cladribine","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"generic","value":"cytarabine","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"modality","value":"Low-Intensity Chemotherapy","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"modality","value":"Nucleoside Analog","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"sample_size","value":"n=190","value_numeric":190},{"paper_doi":"10.1002/ajh.70328","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"study_design","value":"Phase II Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"warning","value":"Single-arm design; no head-to-head comparator, so superiority over standard venetoclax + azacitidine cannot be established from this study alone.","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the notably high CR/CRi and MRD-negativity rates with long-term OS, but should be confirmed in randomized trials.","value_numeric":null},{"paper_doi":"10.1002/ajh.70328","tag_type":"warning","value":"TP53-mutated subgroup outcomes are not separately reported in the abstract despite TP53 status being noted; clinicians should interpret TP53-wild type results with caution regarding applicability to TP53-mutated patients.","value_numeric":null}],"summaries":{"what_studied":"Phase II trial evaluating cladribine + low-dose cytarabine + venetoclax alternating with azacitidine + venetoclax in 190 older or unfit patients (median age 68, range 47–84) with newly diagnosed AML; 64% had adverse-risk disease by ELN 2022.","key_result":"CR/CRi rate was 84% overall (91% in TP53-wild type); MRD-negative CR/CRi 75% overall (77% TP53-wild type); median OS 52 months, 2-year OS 60%, 5-year OS 45%; 4- and 8-week mortality 1% and 3%; 44% of responders proceeded to allogeneic HCT.","limitations":"Single-arm phase II design with no comparator arm limits causal inference; high adverse-risk proportion (64%) may affect generalizability; TP53-mutated outcomes not separately detailed despite inclusion.","practice_takeaway":"This regimen produced deep, durable responses in older/unfit AML patients—including those with adverse-risk disease—with low early mortality; it may be a strong frontline option, especially for patients who are transplant-eligible."}},{"doi":"10.1182/blood.2025030630","pmid":"41770817","title":"Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-03-02T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025030630","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-16T13:54:36.620Z","updated_at":"2026-06-16T13:54:36.620Z","tags":[{"paper_doi":"10.1182/blood.2025030630","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"brand","value":"Gazyva","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"condition","value":"Chronic Lymphocytic Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"bendamustine","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"fludarabine","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"obinutuzumab","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"modality","value":"Anti-CD20 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"sample_size","value":"n=166","value_numeric":166},{"paper_doi":"10.1182/blood.2025030630","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"PFS data were immature at the time of this primary analysis; long-term survival outcomes remain unknown.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"The comparator arm used two different regimens (FCR or BR), chosen at investigator discretion, which may confound cross-arm comparisons.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"The impact_flag 'confirms_prior' was assigned because the authors explicitly state these results confirm and extend findings from the GAIA-CLL13 trial.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"The trial enrolled only fit patients (CIRS ≤6, CrCl ≥70 mL/min) without del(17p)/TP53 mutations; results should not be extrapolated to unfit or high-risk CLL populations.","value_numeric":null}],"summaries":{"what_studied":"Phase 3 RCT (CRISTALLO, NCT04285567) comparing fixed-duration venetoclax-obinutuzumab (VenO, n=80) vs FCR/BR (n=86) as first-line therapy in fit CLL patients (CIRS ≤6, CrCl ≥70 mL/min, no del(17p)/TP53 mutations); primary endpoint was uMRD (<10⁻⁴) in peripheral blood at month 15 by NGS.","key_result":"VenO met the primary endpoint: 81.3% achieved uMRD (<10⁻⁴) in PB at month 15 vs 54.7% with FCR/BR (P=.0004). Deeper responses were also superior: 65.0% vs 25.6% achieved uMRD (<10⁻⁶) in PB at month 15. BM uMRD (<10⁻⁴) at EOT was 70.0% (VenO) vs 38.4% (FCR/BR). Fewer patients progressed or died with VenO (7 vs 13); PFS analysis was not yet mature.","limitations":"- Follow-up was too short for a meaningful PFS comparison at the first planned interim analysis.\n- The trial excluded del(17p)/TP53-mutated patients, limiting generalizability to higher-risk CLL.\n- Patients in the FCR/BR arm received two different regimens (FCR or BR), introducing heterogeneity in the comparator.","practice_takeaway":"For fit, treatment-naive CLL patients without del(17p)/TP53 mutations, fixed-duration VenO achieves significantly deeper MRD responses than FCR or BR—including at the stringent <10⁻⁶ threshold—with a manageable and predictable safety profile. Obinutuzumab debulking eliminated high TLS risk before venetoclax initiation, and no clinical TLS occurred, supporting this sequencing strategy."}}],"initialOffset":16,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"BCL-2 Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"BCL-2 Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"BCL-2 Inhibitor"}}}]]

Papers